 Frequency Therapeutics Inc NASDAQ: FREQ shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss SNHL. The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test. 